{"pmid":32379918,"title":"Coagulopathy of COVID-19 and antiphospholipid antibodies.","text":["Coagulopathy of COVID-19 and antiphospholipid antibodies.","Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported.","J Thromb Haemost","Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M","32379918"],"abstract":["Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported."],"journal":"J Thromb Haemost","authors":["Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379918","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14893","topics":["Diagnosis"],"weight":1,"_version_":1666262687574654978,"score":9.490897,"similar":[{"pmid":32379935,"title":"Response to \"Lupus anticoagulant is frequent in patients with Covid-19\".","text":["Response to \"Lupus anticoagulant is frequent in patients with Covid-19\".","We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.","J Thromb Haemost","Tang, Ning","32379935"],"abstract":["We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain."],"journal":"J Thromb Haemost","authors":["Tang, Ning"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379935","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14890","weight":0,"_version_":1666262687570460673,"score":440.12012},{"pmid":32324958,"title":"Lupus anticoagulant is frequent in patients with Covid-19.","text":["Lupus anticoagulant is frequent in patients with Covid-19.","Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients.","J Thromb Haemost","Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard","32324958"],"abstract":["Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients."],"journal":"J Thromb Haemost","authors":["Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324958","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14867","topics":["Treatment"],"weight":1,"_version_":1666138493881942016,"score":366.46313},{"pmid":32470207,"title":"Frequency of lupus anticoagulant in Covid-19 patients.","text":["Frequency of lupus anticoagulant in Covid-19 patients.","We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (Harzallah et al.(1) ). Bowles et al.(2) and Helms et al.(3) have confirmed these results in new publications. Tang(4) has reported discordant data. He has found that very few tested covid-19 patients had positive LAC in a small series (n=12). Bowles et al. have found that LAC were positive in 91% of patients (n=34) with high activated partial thromboplastin time (aPTT).","J Thromb Haemost","Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard","32470207"],"abstract":["We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (Harzallah et al.(1) ). Bowles et al.(2) and Helms et al.(3) have confirmed these results in new publications. Tang(4) has reported discordant data. He has found that very few tested covid-19 patients had positive LAC in a small series (n=12). Bowles et al. have found that LAC were positive in 91% of patients (n=34) with high activated partial thromboplastin time (aPTT)."],"journal":"J Thromb Haemost","authors":["Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470207","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jth.14937","weight":0,"_version_":1668167110002475009,"score":198.90404},{"pmid":32425261,"pmcid":"PMC7227496","title":"Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.","text":["Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.","*COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.*Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.*Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.","Thromb Res","Galeano-Valle, F","Oblitas, C M","Ferreiro-Mazon, M M","Alonso-Munoz, J","Del Toro-Cervera, J","Demelo-Rodriguez, P","32425261"],"abstract":["*COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.*Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.*Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low."],"journal":"Thromb Res","authors":["Galeano-Valle, F","Oblitas, C M","Ferreiro-Mazon, M M","Alonso-Munoz, J","Del Toro-Cervera, J","Demelo-Rodriguez, P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425261","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.thromres.2020.05.017","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667352728760745984,"score":169.58522},{"pmid":32330303,"title":"Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","text":["Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang","32330303"],"abstract":["Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330303","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25930","keywords":["covid-19","igg","igm","sars-cov-2","diagnosis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494560370688,"score":157.52751}]}